UA040169 MDC/CCL22 Protein, Human
- 公司名稱(chēng) 杭州斯達(dá)特生物科技有限公司
- 品牌 Starter/斯達(dá)特
- 型號(hào) UA040169
- 產(chǎn)地 江蘇 南京
- 廠商性質(zhì) 生產(chǎn)廠家
- 更新時(shí)間 2025/7/15 21:09:19
- 訪問(wèn)次數(shù) 44
聯(lián)系方式:王修明13774214275 查看聯(lián)系方式
聯(lián)系我們時(shí)請(qǐng)說(shuō)明是化工儀器網(wǎng)上看到的信息,謝謝!
CCL22 is a macrophage-derived immunosuppressive chemokine that recruits regulatory T cells through the CCL22:CCR4 axis. It was shown to play a key role in suppressing anti-cancer immune responses in different cancer types. The chemokine CCL22, predominately produced by dendritic cells (DCs), regulates T reg migration via binding to its receptor CCR4. CCL22 controls T cell immunity, both by recruiting T regs to the tumor tissue and by promoting the formation of DC-T reg contacts in the lymph node. There was article showed that tumor-associated macrophages (TAMs) produced an abundance of C-C motif chemokine 22 (CCL22), whose expression in the tumor stroma was positively associated with the level of intratumoral phospho-focal adhesion kinase (pFAK Tyr397), tumor metastasis and reduced patient survival.